03174 CSOP China Healthcare Disruption Index ETF
- 1.852
- +0.004+0.22%
Nomura Adjusts Wuxi Apptec's Price Target to 62.75 Yuan From 99.16 Yuan, Keeps at Buy
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.16 From HK$6.63, Keeps at Buy
Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.41 From HK$8.98, Keeps at Buy
Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy
Nomura Adjusts Innovent Biologics' Price Target to HK$55.31 From HK$54.51, Keeps at Buy
Nomura Adjusts Akeso's Price Target to HK$52.80 From HK$48.84, Keeps at Buy
Nomura Adjusts Wuxi Biologics' Price Target to HK$58.44 From HK$82.69, Keeps at Buy
Nomura Adjusts Innovent Biologics' Price Target to HK$54.51 From HK$45.73, Keeps at Buy
INNOVENT BIOLOGICS(1801.HK):MAZDUTIDE(9MG)CONTINUES TO SHOW ITS BIC POTENTIAL WITH 48-WEEK RESULTS
Nomura Adjusts Wuxi Apptec's Price Target to HK$121.70 From HK$98.96, Keeps at Buy
Nomura Adjusts Wuxi Apptec's Price Target to 139.96 Yuan From 113.43 Yuan, Keeps at Buy
Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$13.01 From HK$19.49, Keeps at Buy
Analysts' Top Technology Picks: Alphabet Class A (GOOGL), WuXi AppTec Co., Ltd. Class H (HK:2359)
Nomura Adjusts Wuxi Biologics' Price Target to HK$82.69 From HK$86.68, Keeps at Buy
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$86.86 From HK$94.91, Keeps at Buy
Wuxi Biologics Target Price Cut to HK$84.90 From HK$94.00 by Daiwa Capital>2269.hk
Nomura Adjusts Wuxi Apptec's Price Target to HK$126.17 From HK$136.77, Keeps at Buy
Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$10.63 From HK$11.27, Keeps at Buy
Nomura Adjusts Akeso's Price Target to HK$50.14 From HK$46.04, Keeps at Buy
Nomura Adjusts WuXi Biologics' Price Target to HK$94.91 From HK$97.78, Keeps at Buy